Radiotherapy Dose Escalation Shows No Added Toxicity in NSCLC

Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy

HONG KONG, April 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is both pleased and honored to announce that its global first-in-class PD-1/VEGF bispecific antibody, ivonescimab, in combination with chemotherapy, has demonstrated strongly positive results in the…

Radiotherapy Dose Escalation Shows No Added Toxicity in NSCLC

Researchers used fluorodeoxyglucose PET to guide their escalation of radiotherapy doses in patients with locally advanced non–small cell lung cancer. Medscape Medical News

Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.

Ivonescimab Plus Chemo Shows Stronger NSCLC Response Than Tislelizumab Combo

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 trial.

Ivonescimab Plus Chemo May Slow Advanced NSCLC Progression

In patients with advanced squamous non–small cell lung cancer, ivonescimab plus chemo was associated with progression-free survival results.

First-Line Ivonescimab Plus Chemo Improves PFS in Advanced Squamous NSCLC

Ivonescimab plus chemotherapy met the primary PFS end point vs tislelizumab plus chemotherapy in advanced squamous NSCLC.